{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:40:45Z","timestamp":1791502845644,"version":"4.3.4"},"reference-count":30,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,4,1]]},"abstract":"<jats:p>BACKGROUND. Persistent pulmonary hypertension (PPHN) occurs in as many as 6.8 of 1000 live births. Mortality is \u223c10% to 20% with high-frequency ventilation, surfactant, inhaled nitric oxide, and extracorporeal membrane oxygenation but is much higher when these therapies are not available. Sildenafil is a phosphodiesterase inhibitor type 5 that selectively reduces pulmonary vascular resistance.<\/jats:p>\n                  <jats:p>OBJECTIVE. Our goal was to evaluate the feasibility of using oral sildenafil and its effect on oxygenation in PPHN.<\/jats:p>\n                  <jats:p>DESIGN. This study was a proof-of-concept, randomized, masked study in infants &amp;gt;35.5 weeks' gestation and &amp;lt;3 days old with severe PPHN and oxygenation index (OI) &amp;gt;25 admitted to the NICU (Hospital Nin\u0303o Jesu\u0301s, Barranquilla, Colombia). The sildenafil solution was prepared from a 50-mg tablet. The first dose (1 mg\/kg) or placebo was given by orogastric tube &amp;lt;30 minutes after randomization and every 6 hours. Preductal saturation and blood pressure were monitored continuously. OI was calculated every 6 hours. The main outcome variable was the effect of oral sildenafil on oxygenation. Sildenafil or placebo was discontinued when OI was &amp;lt;20 or if there was no significant change in OI after 36 hours.<\/jats:p>\n                  <jats:p>RESULTS. Six infants with an OI of &amp;gt;25 received placebo, and 7 received oral sildenafil at a median age of 25 hours. All infants were severely ill, on fraction of inspired oxygen 1.0, and with similar ventilatory parameters. Intragastric sildenafil and placebo were well tolerated. In the treatment group, OI improved in all infants within 6 to 30 hours, all showed a steady improvement in pulse oxygen saturation over time, and none had noticeable effect on blood pressure; 6 of 7 survived. In the placebo group, 1 of 6 infants survived.<\/jats:p>\n                  <jats:p>CONCLUSIONS. Oral sildenafil was administered easily and tolerated as well as placebo and improved OI in infants with severe PPHN, which suggests that oral sildenafil may be effective in the treatment of PPHN and underscores the need for a large, controlled trial.<\/jats:p>","DOI":"10.1542\/peds.2005-0523","type":"journal-article","created":{"date-parts":[[2006,4,3]],"date-time":"2006-04-03T17:23:11Z","timestamp":1144084991000},"page":"1077-1083","source":"Crossref","is-referenced-by-count":264,"title":["Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study"],"prefix":"10.1542","volume":"117","author":[{"given":"Hernando","family":"Baquero","sequence":"first","affiliation":[{"name":"Division of Neonatology, Universidad del Norte, Barranquilla, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amed","family":"Soliz","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Miami Children's Hospital, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy","family":"Neira","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Universidad del Norte, Barranquilla, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Venegas","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Universidad del Norte, Barranquilla, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Sola","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2006,4,1]]},"reference":[{"key":"2021120902113399000_R1","doi-asserted-by":"crossref","unstructured":"Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med.\u20082002;165:1098\u20131102","DOI":"10.1164\/ajrccm.165.8.2107097"},{"key":"2021120902113399000_R2","doi-asserted-by":"crossref","unstructured":"Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol.\u20082004;43:1149\u20131532","DOI":"10.1016\/j.jacc.2003.10.056"},{"key":"2021120902113399000_R3","doi-asserted-by":"crossref","unstructured":"Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation.\u20082002;105:2398\u20132403","DOI":"10.1161\/01.CIR.0000016641.12984.DC"},{"key":"2021120902113399000_R4","doi-asserted-by":"crossref","unstructured":"Lepore JJ, Maroo A, Pereira NL, et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol.\u20082002;90:677\u2013680","DOI":"10.1016\/S0002-9149(02)02586-9"},{"key":"2021120902113399000_R5","doi-asserted-by":"crossref","unstructured":"Turko IV, Ballard SA, Francis SH, Corbin JD. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol Pharmacol.\u20081999;56:124\u2013130","DOI":"10.1124\/mol.56.1.124"},{"key":"2021120902113399000_R6","doi-asserted-by":"crossref","unstructured":"Moreno L, Losada B, Cogolludo A, et al. Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide\/cyclic GMP pathway. Pediatr Res.\u20082004;56:563\u2013570","DOI":"10.1203\/01.PDR.0000139412.58594.D0"},{"key":"2021120902113399000_R7","doi-asserted-by":"crossref","unstructured":"Shekerdemian LS, Ravn HB, Penny DJ. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res.\u20082004;55:413\u2013418","DOI":"10.1203\/01.PDR.0000112033.81970.C2"},{"key":"2021120902113399000_R8","doi-asserted-by":"crossref","unstructured":"Mikhail GW, Prasad SK, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J.\u20082004;25:431\u2013436","DOI":"10.1016\/j.ehj.2004.01.013"},{"key":"2021120902113399000_R9","doi-asserted-by":"crossref","unstructured":"Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet.\u20082002;360:895\u2013900","DOI":"10.1016\/S0140-6736(02)11024-5"},{"key":"2021120902113399000_R10","doi-asserted-by":"crossref","unstructured":"Garci\u0301a Marti\u0301nez E, Ibarra De la Rosa I, Pe\u0301rez Navero JL, Tejero Mateo I, Expo\u0301sito Montes JF, Sua\u0301rez de Lezo y Cruz Conde J. Sildenafil in the treatment of pulmonary hypertension [in Spanish]. An Pediatr (Barc).\u20082003;59:110\u2013113","DOI":"10.1016\/S1695-4033(03)78161-2"},{"key":"2021120902113399000_R11","doi-asserted-by":"crossref","unstructured":"Karatza AA, Narang I, Rosenthal M, Bush A, Magee AG. Treatment of primary pulmonary hypertension with oral sildenafil. Respiration.\u20082004;71:192\u2013194","DOI":"10.1159\/000076684"},{"key":"2021120902113399000_R12","doi-asserted-by":"crossref","unstructured":"Keller RL, Hamrick SE, Kitterman JA, Fineman JR, Hawgood S. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr Crit Care Med.\u20082004;5:184\u2013187","DOI":"10.1097\/01.PCC.0000113266.26638.AD"},{"key":"2021120902113399000_R13","doi-asserted-by":"crossref","unstructured":"Fernandez Gonzalez N, Rodriguez Fernandez A, Jerez Rojas J, Parrondo Garrido SM, Martinez Mengual L. Oral sildenafil: a promising drug for persistent neonatal pulmonary hypertension [in Spanish]. An Pediatr (Barc).\u20082004;61:567\u2013568","DOI":"10.1016\/S1695-4033(04)78449-0"},{"key":"2021120902113399000_R14","doi-asserted-by":"crossref","unstructured":"Walsh MC, Stork EK. Persistent pulmonary hypertension of the newborn. Clin Perinatol.\u20082001;28:609\u2013627","DOI":"10.1016\/S0095-5108(05)70109-3"},{"key":"2021120902113399000_R15","doi-asserted-by":"crossref","unstructured":"Travadi JN, Patole SK. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr Pulmonol.\u20082003;36:529\u2013535","DOI":"10.1002\/ppul.10389"},{"key":"2021120902113399000_R16","doi-asserted-by":"crossref","unstructured":"Lorch SA, Cnaan A, Barnhart K. Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn. Pediatrics.\u20082004;114:417\u2013426","DOI":"10.1542\/peds.114.2.417"},{"key":"2021120902113399000_R17","doi-asserted-by":"crossref","unstructured":"Kinsella JP, Abhman SH. Clinical approach to inhaled nitric oxide therapy in the newborn with hypoxemia. J Pediatr.\u20082000;136:717\u2013726","DOI":"10.1016\/S0022-3476(00)10660-2"},{"key":"2021120902113399000_R18","doi-asserted-by":"crossref","unstructured":"Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr.\u20082002;141:830\u2013832","DOI":"10.1067\/mpd.2002.129849"},{"key":"2021120902113399000_R19","doi-asserted-by":"crossref","unstructured":"Saygy\u0301ly\u0301 A, Canter B, Iriz E, Kula S, Tunaoglu FS, Olgunturk R, Ozdogan ME. Use of sildenafil with inhaled nitric oxide in the management of severe pulmonary hypertension. J Cardiothorac Vasc Anesth.\u20082004;18:775\u2013776","DOI":"10.1053\/j.jvca.2004.08.021"},{"key":"2021120902113399000_R20","doi-asserted-by":"crossref","unstructured":"Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol.\u20082004;43(12 suppl S):68S\u201372S","DOI":"10.1016\/j.jacc.2004.02.031"},{"key":"2021120902113399000_R21","doi-asserted-by":"crossref","unstructured":"Carroll WD, Dhillon R. Sildenafil as a treatment for pulmonary hypertension. Arch Dis Child.\u20082003;88:827\u2013828","DOI":"10.1136\/adc.88.9.827"},{"key":"2021120902113399000_R22","unstructured":"Lima V, Roque R, Villegas C, Escalante F, Torres A, Leija L. Sildenafil for persistent pulmonary hypertension of the newborn: report of two cases [abstract]. Presented at: a Pediatric Academic Societies\/Society for Pediatric Research meeting; May 14\u201317, 2005; Washington, DC"},{"key":"2021120902113399000_R23","doi-asserted-by":"crossref","unstructured":"de Rosalmeida MC, Saraiva LD, da Graca JR, et al. Sildenafil, a phosphodiesterase-5 inhibitor, delays gastric emptying and gastrointestinal transit of liquid in awake rats. Dig Dis Sci.\u20082003;48:2064\u20132068","DOI":"10.1023\/A:1026151227729"},{"key":"2021120902113399000_R24","doi-asserted-by":"crossref","unstructured":"Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med.\u20081998;338:1397\u20131404","DOI":"10.1056\/NEJM199805143382001"},{"key":"2021120902113399000_R25","unstructured":"Behn D, Potter MJ. Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase. Invest Ophthalmol Vis Sci.\u20082001;42:523\u2013527"},{"key":"2021120902113399000_R26","doi-asserted-by":"crossref","unstructured":"Balacco Gabrieli C, Regine F, Vingolo EM, Rispoli E, Isidori A. Acute electroretinographic changes during sildenafil (Viagra) treatment for erectile dysfunction. Doc Ophthalmol.\u20082003;107:111\u2013114","DOI":"10.1023\/A:1026271404384"},{"key":"2021120902113399000_R27","doi-asserted-by":"crossref","unstructured":"Marsh CS, Marden B, Newsom R. Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. Br J Ophthalmol.\u20082004;88:306\u2013307","DOI":"10.1136\/bjo.2003.021956"},{"key":"2021120902113399000_R28","unstructured":"Volke V, Wegener G, Vasar E. Augmentation of the NO-cGMP cascade induces anxiogenic-like effect in mice. J Physiol Pharmacol.\u20082003;54:653\u2013660"},{"key":"2021120902113399000_R29","doi-asserted-by":"crossref","unstructured":"Milman HA, Arnold SB. Neurologic, psychological, and aggressive disturbances with sildenafil. Ann Pharmacother.\u20082002;36:1129\u20131134","DOI":"10.1345\/aph.1A402"},{"key":"2021120902113399000_R30","doi-asserted-by":"crossref","unstructured":"Wang M, Urenjak J, Fedele E, Obrenovitch TP. Effects of phosphodiesterase inhibition on cortical spreading depression and associated changes in extracellular cyclic GMP. Biochem Pharmacol.\u20082004;67:1619\u20131627","DOI":"10.1016\/j.bcp.2003.12.029"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/4\/1077\/1072639\/zpe00406001077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/4\/1077\/1072639\/zpe00406001077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T04:54:23Z","timestamp":1639025663000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/117\/4\/1077\/70839\/Oral-Sildenafil-in-Infants-With-Persistent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,1]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2006,4,1]]},"published-print":{"date-parts":[[2006,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-0523","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,1]]}}}